
Researchers have discovered a weight-loss compound, TOFA, that promotes fat burning without the typical side effect of muscle mass loss.
The study suggests this could offer a significant advancement over current GLP-1 drugs, which often lead to muscle reduction alongside fat loss.
Clinical trials are being explored to determine if the compound can effectively manage obesity while maintaining physical strength in patients.